Sigma-Aldrich Q3 Revenues Rise 2 Percent as Firm Nears Closure of Merck Deal | GenomeWeb

NEW YORK (GenomeWeb) – Sigma-Aldrich today reported third quarter revenue growth of 2 percent year over year as it nears the completion of a deal to be acquired by Merck KGaA.

The St. Louis-based research tools and chemicals firm reported total revenues of $703 million for the three months ended Sept. 30, up from $690 million for the third quarter of 2014. On an organic basis, sales were up 9 percent year over year, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.